-
Stock Picks for Wednesday May 18, 2011
Tuesday, May 17, 2011 - 5:03pm | 1871( click to enlarge ) Akorn, Inc. (NASDAQ:AKRX) - As long as the stock holds above the $6.50 support level the intermediate-term picture should remain positive. Fresh exposures may be considered on a move past $6.94, with a stop-loss at $6.50. ( click to enlarge ) Radio One, Inc. (NASDAQ:...
-
Watson Pharmaceuticals Announces New Research Showing RAPAFLO Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Tuesday, May 17, 2011 - 4:07pm | 190Watson Pharmaceuticals (NYSE: WPI) Announces New Research Showing RAPAFLO Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome New data presented today show that RAPAFLO significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome. In the...
-
Shire to Establish new Regenerative Medicine Business Unit Through Cash Acquisition of Advanced BioHealing, Inc., Including US Marketed DERMAGRAFT
Tuesday, May 17, 2011 - 4:06pm | 150Shire plc (NASDAQ: SHPGY) announces that it has signed an agreement to acquire Advanced BioHealing, Inc. Mike Cola, President of Shire's Specialty Pharmaceuticals business comments: "This acquisition is a strong and complementary strategic fit for Shire. We will invest in the strengths of...
-
10 Stocks Billionaire Steven Cohen Is Buying
Tuesday, May 17, 2011 - 2:00pm | 246(TheStreet) -- Steven Cohen's SAC Capital, known for its trading-oriented style to investing, made big bets in the first quarter while adding to key positions in Newmont Mining (NYSE: NEM) and communications company CenturyLink (NYSE: CTL). Cohen's Stamford, Conn.-based hedge fund firm, which...
-
VIVUS Announces Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Tuesday, May 17, 2011 - 12:31pm | 113VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American...
-
Pfizer's Anti-TNF-Alpha Nanobody Successfully Completes a Phase II Study and Demonstrates Clinical Proof-of-Concept in Patients With RA
Tuesday, May 17, 2011 - 12:11pm | 162Pfizer's (NYSE: PFE) Anti-TNF-Alpha Nanobody (ATN-103) Successfully Completes a Phase II Study and Demonstrates Clinical Proof-of-Concept in Patients With RA Ablynx today announced top-line results from the recently completed POC Phase II clinical trial of ozoralizumab (ATN-103), an anti-TNF-...
-
Biotech/Pharma Stocks News Alert; Hepatitis C Virus (HCV) FDA News from Aethlon Medical, Vertex Pharmaceuticals, Merck & Company
Tuesday, May 17, 2011 - 11:46am | 1602Point Roberts, WA - May 17, 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector trading alert on Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc (VRTX)., Merck & Company, Inc.(NYSE: MRK) announcing FDA updates on...
-
Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C
Tuesday, May 17, 2011 - 11:30am | 150Merck (NYSE: MRK), known as MSD outside the United States, announced today that it has entered into agreements with Roche (RHHBY), through their respective subsidiaries, to improve treatment, diagnosis and awareness of chronic hepatitis C infection in developed and emerging markets. In addition,...
-
Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)
Tuesday, May 17, 2011 - 9:00am | 48Point Roberts, WA - May 17, 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector trading alert on Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc. (VRTX), Merck & Company, Inc.(NYSE: MRK) announcing FDA updates on...
-
Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)
Tuesday, May 17, 2011 - 9:00am | 48Point Roberts, WA - May 17, 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector trading alert on Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc. (VRTX), Merck & Company, Inc.(NYSE: MRK) announcing FDA updates on...
-
Marina Biotech Announces Pricing of Public Offering; $0.31/Unit, Series A Warrant $0.39/Share
Tuesday, May 17, 2011 - 8:16am | 322Marina Biotech, Inc. (NASDAQ: MRNA) today announced the pricing of an underwritten public offering of 22,318,500 units at a price to the public of $0.31 per unit, for gross proceeds of approximately $6.9 million, before deducting underwriting discounts and commissions and other estimated offering...
-
Piper Jaffray Discontinues Coverage On ISPH
Tuesday, May 17, 2011 - 7:31am | 106Piper Jaffray is discontinuing its coverage on Inspire Pharmaceuticals (NASDAQ: ISPH) as the company has been fully acquired by Merck & Co. (NYSE: MRK). Piper Jaffray most recently rated the stock at Neutral and held a $5 price target on the stock. Says Piper Jaffray, in the report, “Investors...
-
10 Small Cap Value Stocks With Positive Earnings
Monday, May 16, 2011 - 10:53pm | 2857Below is a list of 10 small cap stocks with a positive earnings trend. I use stockscreen123 as a tool and screener to find small cap value stocks with recent earnings surprises. I define value as a stock with a projected current year PE of under 20 and a Price to Earnings growth ratio under 1. ...
-
Some Bullish Setups for Tuesday
Monday, May 16, 2011 - 5:20pm | 1767( click to enlarge ) The earlier bullish outlook remains unaltered. Excellent relative strength to broad market. Elan Corporation, plc (NYSE:ELN) traced out a nice setup and the upside breakout has a lot of power. Volume surged and this breakout looks like it is here to stay. Fresh exposures...
-
Marina Biotech Announces Proposed Public Offering of Common Stock and Warrants
Monday, May 16, 2011 - 4:05pm | 132Marina Biotech (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or...